Dr. Daniel B. Gilmer is an accomplished healthcare and biotechnology executive recognized for his extensive contributions to biopharmaceutical research, commercial strategy, and corporate governance. Having built a robust career spanning prominent pharmaceutical institutions and strategic advisory roles—including leadership positions at Pfizer overseeing major product launches and regulatory reviews—he has also contributed significantly to scientific literature regarding bacteriophage endolysins. Furthermore, he serves as a member of the board of directors for Armata Pharmaceuticals, providing expert guidance on clinical development and commercial operations.